All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-Claudin18.2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human Claudin18.2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-Claudin18.2 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.
CAR Construction : Fig.1 Flow cytometric analysis to determine the specificity of zolbetuximab to CLDN18.2. CLDN18.1 and CLDN18.2 was co-expressed with GFP in CHO-CLDN18.1-GFP and CHO-CLDN18.2-GFP cells, respectively. Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., ... & Shen, L. (2022). Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine, 1-10. |
CAR Construction : Fig.1 PBMC based ADCC analysis of zolbetuximab. Human PBMCs isolated form whole blood were used as the effector cells, and SNU-620 were used as the target cells. The effector to target ratio was equal to 25:1. Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., ... & Shen, L. (2022). Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine, 1-10. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-Claudin18.2 ( IMAB362) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP8942). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION